RESEARCH PAPER
Effects of semaglutide on anthropometric measures, diet, and eating behaviors in obese women: a retrospective observational study
1
Institute of Sport Sciences, Jerzy Kukuczka Academy of Physical Education, Katowice, Poland
2
Department of Rehabilitation, Faculty of Health Sciences in Katowice, Medical University of Silesia
in Katowice, Poland
3
Department of Public Health, Faculty of Public Health in Bytom, Medical University of Silesia
in Katowice, Poland
Submission date: 2026-01-03
Final revision date: 2026-02-07
Acceptance date: 2026-02-10
Online publication date: 2026-02-17
Corresponding author
Tomasz Jurys
Department of Rehabilitation, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, Ziołowa 45/47 Street, 40-635 Katowice, Poland
Department of Rehabilitation, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, Ziołowa 45/47 Street, 40-635 Katowice, Poland
KEYWORDS
TOPICS
ABSTRACT
Background:
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). It is also recommended as part of the therapeutic strategy for individuals with metabolic syndrome or obesity. This study aimed to evaluate the effects of semaglutide administration on body weight reduction, eating behaviors, energy intake, and appetite control in women with diagnosed obesity and insulin resistance.
Material and methods:
The study included 104 women diagnosed with obesity and insulin resistance who tolerated semaglutide therapy without adverse effects.
Results:
Participants using semaglutide demonstrated a mean decrease in daily energy intake of 103 kcal (p=0.034; d=-0.21) compared with baseline. A significant reduction in body weight (mean -2.85 kg) was observed, along with decreases in body fat content, Body Mass Index (BMI), and waist-to-hip ratio (WHR).
Conclusions:
Semaglutide use was associated with appetite suppression, reduced snacking frequency, and a subsequent decrease in body weight and body fat percentage, indicating its beneficial role in weight management among women with obesity and insulin resistance.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used to improve glycemic control in patients with type 2 diabetes mellitus (T2DM). It is also recommended as part of the therapeutic strategy for individuals with metabolic syndrome or obesity. This study aimed to evaluate the effects of semaglutide administration on body weight reduction, eating behaviors, energy intake, and appetite control in women with diagnosed obesity and insulin resistance.
Material and methods:
The study included 104 women diagnosed with obesity and insulin resistance who tolerated semaglutide therapy without adverse effects.
Results:
Participants using semaglutide demonstrated a mean decrease in daily energy intake of 103 kcal (p=0.034; d=-0.21) compared with baseline. A significant reduction in body weight (mean -2.85 kg) was observed, along with decreases in body fat content, Body Mass Index (BMI), and waist-to-hip ratio (WHR).
Conclusions:
Semaglutide use was associated with appetite suppression, reduced snacking frequency, and a subsequent decrease in body weight and body fat percentage, indicating its beneficial role in weight management among women with obesity and insulin resistance.
Share
RELATED ARTICLE
| eISSN: | 2354-0265 |
| ISSN: | 2353-6942 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
